【打印本页】 【下载PDF全文】 【HTML】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 1078次   下载 874 本文二维码信息
码上扫一扫!
利福平抗黄热病毒感染的效果及初步机制
吴兵安1△,钱汐晶1△,吴兴安2,徐铮昊1,罗正汉1,唐海琳1,赵平1,戚中田1*
0
(1. 海军军医大学(第二军医大学)海军医学系生物医学防护教研室, 上海 200433;
2. 空军军医大学基础医学院微生物学教研室, 西安 710032
共同第一作者
*通信作者)
摘要:
目的 检测利福平抗黄热病毒(YFV)感染的效果并初步探索其机制。方法 用不同浓度(0.04、0.2、1、5、25、125、625 μmol/L)的利福平处理人肝癌细胞Huh-7 24 h,通过CCK-8检测利福平的细胞毒性并计算其细胞半数毒性浓度(CC50)。YFV感染Huh-7细胞的同时加入不同浓度(0.04、0.2、1、5、25 μmol/L)的利福平,检测其抗YFV感染的剂量效应,并计算IC50。YFV感染Huh-7细胞的同时加入5 μmol/L利福平,孵育不同时长(2、4、8、12、24 h),检测其抗YFV感染的时间效应。YFV感染Huh-7细胞后,在感染的不同时间段(2、4、6、8、12 h)加入25 μmol/L利福平(药物作用时间2 h,病毒感染2 h),检测其抗YFV感染最显著的起效阶段。利用病毒结合实验、内吞荧光标记实验评价利福平对YFV入侵靶细胞的影响。结果 利福平细胞毒性较弱(CC50为176.9 μmol/L),抑制YFV作用显著(IC50为1.868 μmol/L,P<0.01);动力时间窗、结合和内吞实验表明,利福平能抑制YFV结合、入侵靶细胞(P<0.01),但不影响YFV的内吞过程。此外,利福平在感染后期的复制阶段也有一定的抑制效果(P<0.01)。结论 利福平可抑制YFV感染靶细胞,作用机制主要通过在病毒感染早期的入侵阶段阻断病毒结合靶细胞。
关键词:  利福平  黄热病毒  抗病毒药  感染
DOI:10.16781/j.0258-879x.2021.01.0008
投稿时间:2020-07-22修订日期:2020-11-03
基金项目:国家科技重大专项重大传染病防治课题(2017ZX10304403-003),国家自然科学基金青年科学基金(31700147),陕西省重点研发项目(2019ZDLSF02-03).
Antiviral effect of rifampin on yellow fever virus and its preliminary mechanism
WU Bing-an1△,QIAN Xi-jing1△,WU Xing-an2,XU Zheng-hao1,LUO Zheng-han1,TANG Hai-lin1,ZHAO Ping1,QI Zhong-tian1*
(1. Department of Biomedical Defense, Faculty of Naval Medicine, Naval Medical University (Second Military Medical University), Shanghai 200433, China;
2. Department of Microbiology, College of Basic Medical Sciences, Air Force Medical University, Xi'an 710032, Shannxi, China
Co-first authors.
* Corresponding author)
Abstract:
Objective To explore the effect of rifampin on yellow fever virus (YFV) and its preliminary mechanism. Methods Indicated concentrations of rifampin (0.04, 0.2, 1, 5, 25, 125, 625 μmol/L) were incubated with human liver cancer cells Huh-7 for 24 h. The cytotoxicity of rifampin was measured by CCK-8 assay and the 50% cytotoxic concentration (CC50) was calculated. When Huh-7 cells were infected with YFV, different concentrations of rifampin (0.04, 0.2, 1, 5, 25 μmol/L) were added to detect the dose-response relationship of YFV resistance and to calculate the half inhibition concentration (IC50); rifampin (5 μmol/L) was added and incubated for different exposure time (2, 4, 8, 12, 24 h) to detect the time-effect relationship of YFV resistance. Huh-7 cells were infected with YFV for 2 h, and rifampin (25 μmol/L) was added at different time points (2, 4, 6, 8, 12 h) for 2 h incubation. The most significant anti-YFV stage was detected. The effect of rifampin on YFV invasion was evaluated by virus binding assay and cholera toxin B (CTB)/transferrin (TF) mediated endocytosis experiment. Results Rifampin had a robust anti-YFV effect (IC50=1.868 μmol/L, P<0.01) with low cytotoxicity (CC50=176.9 μmol/L). Kinetic test, binding and endocytosis experiments showed that rifampin could significantly inhibit YFV binding and invading target cells (P<0.01), but did not affect the endocytosis process of YFV. Moreover, rifampin also had inhibitory effect at late YFV replication stage (P<0.01). Conclusion Rifampin can inhibit YFV infection by blocking viral binding to the target cells at early stage of viral entry.
Key words:  rifampin  yellow fever virus  antiviral agents  infection